Examining the impact of biosimilar-to-biosimilar transition on effectiveness and safety

Expert Opin Biol Ther. 2024 Jul;24(7):563-566. doi: 10.1080/14712598.2024.2324123. Epub 2024 Feb 28.

Authors

Anan S Jarab^{1

2

3}, Shrouq R Abu Heshmeh³, Ahmad Z Al Meslamani^{1

2}

Affiliations

¹ College of Pharmacy, Al Ain University, Abu Dhabi, United Arab Emirates.
² AAU Health and Biomedical Research Center, Al Ain University, Abu Dhabi, United Arab Emirates.
³ Pharmacy, Jordan University of Science and Technology, Irbid, Jordan.

PMID: 38404241
DOI: 10.1080/14712598.2024.2324123

No abstract available

Keywords: Biosimilars; cross-switching; efficacy; safety.

Publication types

Editorial

MeSH terms

Biosimilar Pharmaceuticals* / adverse effects
Biosimilar Pharmaceuticals* / therapeutic use
Drug Approval
Humans

Substances

Biosimilar Pharmaceuticals